Head-to-head evidence
GS101 vs stapokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
GS101
Developed by Jiangsu Genscend Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07386743 (registry estimate)
stapokibart
Developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and partners
NCT05265923 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial in 500 adults with moderate-to-severe atopic dermatitis, significantly more patients receiving stapokibart achieved at least a 75% reduction in eczema severity at 16 weeks than those on placebo (66.9% vs 25.8%).
Next expected readout: February 2027 · NCT07106372 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GS101's landscape · stapokibart's landscape